SeekingAlpha · Sep 4, 2026
Annexon, Inc. (ANNX) Virtual Business Update Call Transcript
Annexon (ANNX) Virtual Business Update Call recap: Phase III updates for GBS and geographic atrophy, r
AN
NASDAQ · ANNX
Annexon, Inc.
Healthcare · Biotechnology
$4.37
Down-$0.23 (-5.26%)
Updated Sep 10, 2026, 9:37 PM
SID Score
3.3/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 669.73M
- P/E ratio
- -4.03
- Dividend yield
- 0.00%
- 52-week range
- $4.34 – $6.62
- Volume
- 5.53M
- Avg. volume
- 2.57M
Price performance
ANNX price history
1M range · 20 trading sessions · Daily adjusted prices
ANNX closed at $4.37 after 20 trading sessions, down 18.01% for the selected period.
- Last close
- $4.37
- Period change
- -18.01%
- Period low
- $4.37
- Period high
- $5.50
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 9, 2026 | $4.60 | $4.66 | $4.34 | $4.37 | 5.53M |
| Sep 8, 2026 | $4.76 | $4.785 | $4.64 | $4.67 | 2.14M |
| Sep 4, 2026 | $4.81 | $4.905 | $4.79 | $4.87 | 1.23M |
| Sep 3, 2026 | $4.93 | $5.04 | $4.765 | $4.84 | 2.31M |
| Sep 2, 2026 | $4.90 | $5.075 | $4.78 | $4.93 | 1.84M |
| Sep 1, 2026 | $4.96 | $5.00 | $4.85 | $4.89 | 1.47M |
| Aug 31, 2026 | $4.99 | $5.04 | $4.83 | $4.94 | 2.44M |
| Aug 28, 2026 | $5.18 | $5.205 | $4.945 | $4.97 | 1.62M |
| Aug 27, 2026 | $5.00 | $5.32 | $4.91 | $5.25 | 3.02M |
| Aug 26, 2026 | $5.13 | $5.175 | $4.955 | $4.99 | 2.28M |
| Aug 25, 2026 | $5.13 | $5.225 | $5.085 | $5.15 | 2.94M |
| Aug 24, 2026 | $5.05 | $5.13 | $4.80 | $5.06 | 3.38M |
| Aug 21, 2026 | $5.24 | $5.275 | $5.02 | $5.07 | 1.43M |
| Aug 20, 2026 | $5.41 | $5.465 | $5.105 | $5.18 | 1.67M |
| Aug 19, 2026 | $5.45 | $5.59 | $5.34 | $5.50 | 3.5M |
| Aug 18, 2026 | $5.03 | $5.3078 | $5.02 | $5.28 | 2.24M |
| Aug 17, 2026 | $5.26 | $5.29 | $5.06 | $5.13 | 3.63M |
| Aug 14, 2026 | $5.21 | $5.345 | $5.081 | $5.29 | 2.99M |
| Aug 13, 2026 | $5.36 | $5.40 | $5.195 | $5.26 | 3.12M |
| Aug 12, 2026 | $5.06 | $5.415 | $5.00 | $5.33 | 3.95M |
Latest ANNX news
The latest Smart Investors Daily articles mentioning ANNX.
Stock researchCompany · Overview
ANNX research
Overview
Company profile and research snapshot.
Company profile
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502 for Oral small molecule; and ANX009, for systemic autoimmune diseases.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $14.00
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 1, 2026 | JP Morgan | Overweight | — |
| Aug 13, 2026 | Citizens | Market Perform | — |
| Jul 21, 2026 | Citizens | Market Underperform | — |
| Jul 15, 2026 | Needham | Buy | — |
| May 12, 2026 | Goldman Sachs | Neutral | — |
News briefing
No generated briefing is available yet.
Yahoo · Sep 2, 2026
Annexon to Participate in Upcoming September Investor Conferences
BRISBANE, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people worldwide, today announced that Douglas Love, Esq., president & chief executive officer, will participate in fireside chats during the following September investor conferences: Wells Fargo 21st Annual Healthcare Conference on Wednesday, September 9,
Benzinga · Sep 1, 2026
JP Morgan Maintains Overweight on Annexon, Raises Price Target to $14
JP Morgan analyst Anupam Rama maintains Annexon (NASDAQ:ANNX) with a Overweight and raises the price target from $10 to $14.
Benzinga · Aug 13, 2026
Citizens Upgrades Annexon to Market Perform
Citizens analyst Jonathan Wolleben upgrades Annexon (NASDAQ:ANNX) from Market Underperform to Market Perform.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
